Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Elucidation of an Anti-glutamate Receptor GluR3B for Diagnosis, Research and Drug Discovery in Epilepsy Print
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1451
Dozens of epilepsy types affect altogether 1-2% of the world\'s population. Their aetiology is often unknown, and 20-30% of epilepsy patients do not benefit from any anticonvulsant medication....
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Dozens of epilepsy types affect altogether 1-2% of the world's population. Their aetiology is often unknown, and 20-30% of epilepsy patients do not benefit from any anticonvulsant medication. Such patients may endure several seizures per day and suffer from numerous neurological and neuropsychiatric problems, rendering their lives miserable.

Antibodies (Ab's) to GluR3B peptide are present in 35% of patients with different epilepsies, and are suspected to be pathogenic to the brain, as they can bind neurons, possess an unique ability to activate their antigens (the respective glutamate-receptors), kill neurons, cause multiple brain damage and induce neurobehavioral and cognitive/emotional impairments. On this basis, GluR3B Ab's have to be diagnosed in epilepsy patients, especially in intractable epilepsy unresponsive to conventional therapies, and before drastic brain surgery is performed.

Aims/Hypothesis

The finding of GluR3B Ab's would be suggestive of the need for immunotherapy.

Research

A unique anti-GluR3B monoclonal antibody Glu149/29/61 has been developed, which could be used for developing a new diagnostic kit to detect neuropathogenic human anti-GluR3B in serum and CSF of patients with epilepsy. The patient's GluR3B Ab's would compete and displace the GluR3B mAb's of its ligand: the GluR3B peptide. The presence of GluR3B Ab's in a patient, would indicate that autoimmunity against GluR3 may underlie the patient's neuropathology and a) would suggest the initiation of an immune-based therapy b) prevent useless and dangerous brain surgery c) prevent non-effective medication.

In addition the unique GluR3B monoclonal antibody could be used to screen a potential drug for 'Autoimmune Epilepsy'. The GluR3B monoclonal antibody could be used to screen for a molecule (i.e. Anti-idiotypic antibodies) that would block the GluR3 autoantibodies and their detrimental neuropathological effects.

Conclusion

Scientists from the Weizmann Institute of Science have discovered a unique anti-GluR3B monoclonal antibody Glu149/29/61.

Relevance/Opportunity

Please enquire quoting reference no. 1451 regarding licensing or codevelopment partnerships.
FEATURED
Last Updated May 2015
Technology Type DIAGNOSTIC
Phase of Development PRECLINICAL
CORPORATION